What Happened to the Plans for a Smart Contact Lens for Diabetics?
Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose…
January 25, 2018 - 5 minutes
Novartis
Novartis Takes Genmab’s Leukemia Drug Off the Market
Genmab's leukemia drug will be available around the world through compassionate use programs, while it will…
January 22, 2018 - 3 minutes
Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017
Now that we've got the bad news out of the way, we're here to spread…
December 18, 2017 - 9 minutes
The FDA Approves the First CAR-T Cell Therapy for Cancer
The FDA has approved Novartis' CAR-T therapy Kymriah, opening the way for a new generation…
August 31, 2017 - 3 minutes
Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks
European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’…
August 29, 2017 - 2 minutes
Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns
Editor's Note: Novartis did note a death from cerebral hemorrhage in its hearing with the…
July 11, 2017 - 3 minutes
Novartis Scores Major Phase III Win with New Cardiovascular Drug
Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III…
June 22, 2017 - 2 minutes
Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials
Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive…
June 20, 2017 - 2 minutes
Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx
Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants…
June 15, 2017 - 1 minute
UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech
The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and…
June 15, 2017 - 3 minutes
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T…
May 2, 2017 - 2 minutes
Novartis Negotiates its Way into the US Migraine Market
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring…
April 25, 2017 - 2 minutes
